Biotech Startups

Phoenix Molecular Designs (PhoenixMD) is a biotechnology company developing targeted breast cancer therapeutics, including PMD-026, a first-in-class RSK2 inhibitor in Phase 2 clinical trials paired with a companion diagnostic. The company applies medicinal chemistry, computational modeling, and cancer biology to treat breast cancer and other cancers.

3 investors

Photys Therapeutics develops bifunctional small-molecule medicines that use induced proximity to recruit kinases and drive targeted protein phosphorylation, aiming to modulate and repair disease-driving proteins. It is building a therapeutic pipeline for autoimmune, inflammatory, oncology, and cardiometabolic diseases.

3 investors

Phyx44 designs novel proteins engineered for food applications using precision fermentation and protein engineering, serving food manufacturers seeking specific taste, texture, and nutritional functionality. The company produces animal-free proteins through scalable fermentation processes.

3 investors

Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases. The company focuses on oral drug formulation in the biotech and pharmaceutical space.

3 investors

Moonwalk Biosciences is a life sciences company operating in the biotech sector. This page profiles a member of its leadership team.

3 investors

Polyphron is using AI and automation to produce human tissue at scale, providing ground-truth data for AI biology and developing therapeutics based on immune-compatible iPSC-derived grafts.

3 investors

Ponda is a biomaterials company developing textiles from regenerative fibres, specifically processing cattails grown in regenerative wetlands, as an alternative to fabrics sourced from ancient and endangered forests. The company serves apparel brands, designers, and retailers seeking sustainable textile solutions that protect global ecosystems.

3 investors

Poseida Therapeutics develops cell therapy candidates and related platform technologies for healthcare applications. The company was acquired by Roche, with its programs now developed by Genentech.

3 investors

Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy. Its portfolio uses both small molecule (Cerebrum) and antisense oligonucleotide (Solidus) platforms informed by human genetics and translational science.</parameter> <parameter name="founders">[]

3 investors

Precision for Medicine is a contract research organization that provides clinical trial management and regulatory support for drug development programs, including oncology, hematology, cell and gene therapy, CAR-T, and radiopharmaceutical trials. It serves pharmaceutical and biotech sponsors running multinational Phase I–IV studies.

3 investors

Precision Medicine Group provides biomarker-driven research and development services and commercialization support for pharmaceutical and life science companies across drug development, manufacturing, and market access.

3 investors

Prenetics is a health company that operates in genetic testing and precision diagnostics and runs the consumer health supplement brand IM8, sold direct-to-consumer and through Amazon and social commerce channels. The company markets longevity and wellness products globally, including partnerships with athletes and sports organizations.

3 investors

Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.

3 investors

3 investors

Priothera is a clinical-stage biopharmaceutical company developing mocravimod, an investigational immune modulator intended as a maintenance therapy for allogeneic hematopoietic cell transplantation. Its work targets hematological malignancies such as acute myeloid leukemia, aiming to enhance the graft-versus-leukemia effect while reducing graft-versus-host disease.

3 investors

Profluent develops AI foundation models combined with an in-house wet lab to design proteins for applications ranging from human health to industrial uses. It works with partners to author natural and de novo proteins optimized for specific commercial use-cases.

3 investors

Profound Medical develops real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. The company's TULSA-PRO therapeutic system enables precise ablation of diseased prostate tissue in a commercial-stage medical technology setting.

3 investors

Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells. The company targets the significant unmet need for remyelinating treatments that could repair damage caused by MS and potentially restore lost function.

3 investors

Project Eaden develops plant-based meat products using advanced food science techniques, targeting consumers who want sustainable protein alternatives without compromising on taste. The company combines culinary expertise with scientific innovation to create meat alternatives optimized for flavor and environmental impact.

3 investors

Projectus builds empathy-first AI grounded in behavioral science that decodes human emotions and behaviors to deliver actionable insights. It serves pharma, biotech, and commercial teams.

3 investors

Promaxo develops a compact, office-based MRI system designed for point-of-care use, with applications including image-guided prostate interventions. The company operates in the medical imaging and medical device sector.

3 investors

ProQR develops medicines for patients with unmet medical needs, focusing on therapeutic development in biotech.

3 investors

ProteinQure is a clinical-stage biotech company that designs novel peptides for therapeutic delivery using its proprietary ProteinStudio computational platform powered by AI and molecular simulations. The company focuses on peptide-drug conjugates for tissue-specific and cell-specific delivery of therapeutics, with applications in oncology, renal disease, and blood-brain barrier transport.

3 investors

Q.bio provides quantitative biology assessments and longitudinal health monitoring for preventive care, offering comprehensive measurable exams at the scale of premium care providers.

3 investors